THE PROGNOSIS OF PATIENTS WITH END STAGE RENAL DISEASE AND SEVERE CONGESTIVE HEART FAILURE AFTER RENAL TRANSPLANTATION
|
|
- Annice Simon
- 6 years ago
- Views:
Transcription
1 THE PROGNOSIS OF PATIENTS WITH END STAGE RENAL DISEASE AND SEVERE CONGESTIVE HEART FAILURE AFTER RENAL TRANSPLANTATION Cristina Bucşa 1, Dorina Tacu 1, Cristina Ceck², Eminee Kerezsy 1, Liliana Domnişor 1, Denise Daia 1, and Ionel Sinescu 1 1 Center of Urological Surgery, Dialysis and Renal Transplantation, Fundeni Clinical Institute, ² Prof. C.C. Iliescu Institute of Cardiovascular Diseases, Bucharest, Romania Address for correspondence: Cristina Alina Bucşa, MD 1 Center of Urological Surgery, Dialysis and Renal Transplantation, Fundeni Clinical Institute, Fundeni Str., No. 258, sector 2, code: , Bucharest, Romania cristinabucsa@yahoo.com Abstract Cardiovascular diseases are the main cause of morbidity and mortality in end stage renal disease (ESRD) patients. Over the past years the overall mortality rates have gradually decreased. One explanation for the overall decrease in mortality rates in ESRD patients has been a decrease in the incidence of deaths from cardiac causes. Heart failure (HF) affects many of these patients and the indication of kidney transplantation is controversial in certain situations like patients with high perioperative risk. 1
2 The aim of this study is to evaluate the impact of kidney transplantation in ESRD patients with severe congestive heart failure. Key words: end stage renal disease, severe heart failure, renal transplantation, risk of death. Introduction: Cardiovascular disease is the most important cause of death for both dialysis and transplant patients. About half of the deaths in dialysis patients are caused by cardiovascular disease. Transplant patients fare much better with expected remaining life time that are approximately two thirds as long as those found in the general population (1). Symptomatic cardiac disease results from disorders of left ventricular (LV) structure and function and from disorders of perfusion. Subjects with myocardial failure can have symptomatic heart failure (HF) or asymptomatic ventricular dysfunction. Symptoms of exercise intolerance are typically assessed by the New York Heart Association (NYHA) functional classification (2). Upon starting dialysis, 37% of patients have had a previous episode of heart failure, doubling the risk of death (3). The remaining patients will develop heart failure at a rate of about 10%/ year (4). Both systolic and/or diastolic function may be impaired. 15% of patients starting dialysis therapy have systolic dysfunction of the left ventricle (5). The prevalence of diastolic dysfunction at dialysis inception is unknown, but is likely to be high (6). Either systolic or diastolic dysfunction can lead to clinically evident congestive heart failure (CHF). Cardiomyopathy risk factors in CKD (7) patients are: 2
3 I. LV volume overload salt and water overload arterio-venous fistula anemia an independent risk factor for CHF (16) II. LV pressure overload hypertension arteriosclerosis aortic stenosis III. Other risk factors uremic related like hypoalbuminemia (malnutrition, catabolic status, waste thru peritoneal dialysis or urine) hyperhomocysteinemia, hyperparathyroidism (myocardial fibrosis)(21) inflammation (CRP, cytokines TNF, IL6)(15) Pathogenesis of cardiomyopathy in chronic uremia (9): 3
4 Hypertension Aortic stenosis Salt+ water overload AV fistula LV pressure overload LV volume overload Concentric LVH Excentric LVH Vascular remodeling Overload cardiomyopathy HPTH Malnutrition Other factors Myocyte death Myocardial fibrosis Decreased capillary density Decreased capillary perfusion LV dilation LV hypertrophy Diastolic dysfunction (Symptomatic LV failure) Systolic dysfunction (Diminished contractility) The diagnosis consists in: symptoms of heart failure 4
5 physical examination ECG chest X-ray echocardiogram. Echocardiography is the most important tool for the diagnosis of CHF in CKD patients. M-mode echocardiography is an useful test for the measurement of LV dilatation, hypertrophy and dysfunction. Assessment of cardiac valves and movement of walls requires 2-D echocardiography and for the assessment of diastolic dysfunction Doppler study is useful. A Canadian study followed 432 patients between 1983 to 1991 and showed a variety of abnormalities: most common was concentric LV hypertrophy found in 42% of patients, eccentric LV hypertrophy in 23%, isolated LV dilatation in 4% and systolic dysfunction in 16%. Only 16% had a normal echocardiogram (8). Similar data (about 75% patients with LVH) showed USRDS (United States Renal Data System) (1). However, LV volume fluctuates in haemodialysis patients. Therefore it is necessary to perform echocardiography at the patients dry weight the day after dialysis. In patients with anemia the increase in cardiac preload alters the pattern of Doppler signals that is used for the evaluation of diastolic function. Management of heart failure: Numerous clinical trials have shown that angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-blockers and spironolactone have dramatically improved the survival in patients with congestive heart failure and normal 5
6 renal function. The available data indicate that the administration of ACE inhibitors and ARBs, both well known to nephrologists because of their effects on the progression of renal failure, is associated with a better survival in cardiac patients with mild renal failure. Because subjects with renal insufficiency have been under-represented in the above trials, there is rather limited information on the effects of the above medications in patients with advanced renal failure and/or maintenance dialysis (10). The effects of beta-blockers are not believed to be different in patients with renal failure from those in patients with normal kidney function. The effects of carvedilol, a beta-blocker reported to lead to a significant reduction in cardiac mortality in patients with mild renal failure, have not been assessed in most published studies. Recently, carvedilol has been reported to induce relaxation of renal glomerular microvasculature via an increased nitric oxide (NO) release from endothelial cells (11). This novel mechanism may be the reason for the decline in renal function occasionally observed in patients with mild to moderate renal insufficiency. In haemodialysis patients with dilated cardiomyopathy, however, a controlled study showed that carvedilol administration increased the ejection fraction and significantly reduced the cardiovascular mortality (12). Treatment of anemia has opened a new frontier in the management of heart failure. Appropriate treatment of anemia, improves ventricular function and clinical status. (13) Degree of anemia is directly related to the morbidity of cardiac disease. Correction of anemia with parenteral iron preparations and with recombinant erythropoietin, however, is associated with an improved cardiac function, a reduced need for hospitalization, a more stable renal function and an improved quality of life (14) (15). Removal of marked fluid overload is one of the most demanding and difficult to obtain challenges in the management of severe congestive heart failure, particularly in patients 6
7 refractory to diuretic therapy. Over the years, several centers published their experience in regarding the use of peritoneal dialysis in acute and chronic management of severe heart failure (16) (17). Peritoneal dialysis is believed by many nephrologists to be the modality of choice in the management of patients with III and IV stages of heart failure, either as palliative therapy or as a bridge to transplantation. Hemodiafiltration is an effective treatment for patients with advanced CHF (std III-IV NYHA) when cytokines have to be cleared and diuretic responsiveness needs to be restored (18). Nocturnal haemodialysis (NHD), a novel mode of renal replacement therapy, may be more effective than conventional haemodialysis in reducing intravascular volume or in removing uremic toxins with vasoconstrictor or myocardial depressant actions, and may, therefore, improve the left ventricular (LV) systolic function of patients with coexisting cardiac and renal failure.(19) Kidney transplant recipients show improvements in cardiac function, regression of LVH and reduction in hospitalizations for CHF compared with the time before transplantation (20). Subjects and methods: This is a retrospective study between January 2002 and January 2006 on 464 renal transplants. 34 of them (7.3 %) had severe heart failure NYHA III/IV and left ventricular ejection fraction (LVEF) under 40%. 3 patients received kidneys from cadaver and 31 from living donors. The mean age was 39 ±6.7 years and the mean dialysis duration was 26.1±7 months. There were 11 males, and 23 females, 21 on HD and 13 on PD. The causes of renal failure were chronic glomerulonephritis (6), polycystic kidney disease (5), nephrosclerosis (4), interstitial nephritis (4), diabetes (3), others (6) and not determined (6). 7
8 Immunosuppressive drug treatment consisted of cyclosporine (6 mg/kg/day) or tacrolimus (0,15 mg/kg/day), mycophenolat mofetil (2000 mg/day) and prednisone. All patients had a history of hypertension (defined as blood pressure >140/90 and/or use of antihypertensive medication). 31 patients were receiving antihypertensive medication (11 receiving longacting calcium channel blockers and 23 receiving ACE inhibitors). All patients were initially studied before transplantation, at the time of discharge, 28±6 days after surgery. The tests were repeated at 12 months after the operation. We made clinical, ECG, biological and ultrasonographic evaluation. All subjects underwent uni- and bi-dimensional echocardiography and Doppler examination. End-diastolic ventricular diameter (LVDD), end-systolic ventricular diameter (LVSD), left ventricular posterior wall thickness (LVPW) and interventricular septum (IVS) were measured. Mitral valve flow velocities were obtained. Statistics: Values are expressed as means ± standard error of the mean. The student's tests were applied to the data. A P value of <0.05 was considered significant. Results: Clinical evaluation showed a significant improvement of NYHA functional classification with reduction from an average III-IV to NYHA class I. This clinical improvement was positive correlated with correction of hypervolaemia (medium body weight loss was 5.1±1.2 kg), rising of hematocrit level (32%±5), correction of high blood pressure, and good graft function (medium serum creatinine 1.8±0.9 mg/dl). The most important arrhythmias before transplantation were sinus tachycardia (for 24 patients) and atrial fibrilation (for 6 patients). 8
9 Rhythm control was achieved for 33 patients, 3 of patients with atrial fibrilation underwent a spontaneously conversion to sinusal rhythm (Figure 1). Echocardiograms (Figure 2) showed a significant reduction of left posterior wall thickness from 12.2±0.2 to 11.3 mm at 12 months (P<0.05) (Figure 3a). There was also significant reduction of LV end-diastolic diameter from 68.1±0.5 to 55.3±0.2 at 12 months (P<0.001) (Figure 3b), LV end-systolic diameter from 57.2±0.5 to 39.3±0.4 at 12 months (P<0.001) (Figure 3c), pulmonary hypertension from 66±11 mmhg to 34,3±5 mmhg at 12 months (P<0.001) (Figure 3d) and medium LVEF increased from 28,5%±10 to 51%±11 at 12 months (P<0.001) (Figure 3e). One patient underwent a successful heart transplant because of ventricular function deterioration after kidney transplantation. The perioperative and 12 months mortality was zero (Figure 4). Discussions: It is already accepted that pre transplant coronary artery disease, cardiomyopathy and diabetes are associated with increased risk of cardiovascular events after the operation. Despite the benefits of kidney transplantation (20) the presence of preoperative echocardiography abnormalities including systolic dysfunction, LVH and ventricular dilatation is associated with premature death even after transplantation (21). This alteration couldn t be completely reversed after the transplantation even though our study showed important improvements in clinical manifestations and myocardial structure. The most important result of our study is the lack of the perioperative mortality and also the lack of mortality at 12 months after the transplantation even though the U. S. Renal Data System (USRD) found an increased short term risk of death after transplantation. (1) Heart 9
10 failure has been identified in several studies as being associated with a poorer outcome when noncardiac surgery is performed. In a study by Goldman et al (22), both the presence of a third heart sound and signs of HF were associated with a substantially increased risk during noncardiac surgery. Among patients with heart failure NYHA II, III and IV, total mortality was 7 1%, 15 0% and 28 0%, respectively (23). We also have to discuss the limitations of this study: the follow up period could be too short. The number of the patients in our study group could be too small for a statistical analysis. We didn t have a control group consist of dialysis patients. Conclusions: Kidney transplantation showed important improvements in clinical manifestations and myocardial structure even in severe congestive HF. These good results are positive correlated with correction of risk factors uremic related like anemia, fluid overload, hypoalbuminemia, hyperparathyroidism etc. References: 1. US Renal Data System. Annual Data Report. National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD:2007: 2. Braunwald E Heart Disease: A Textbook of Cardiovascular Medicine, W. B. Saunders Company, Phyladelphia, Pennsylvania, Foley R, Parfrey P, Hefferton D, Kent G, Murray D, Barre P. Advance prediction of early death in patients starting maintenance dialysis. Am J Kidney Dis, 1994; 23:
11 4. 1Churchill D, Taylor D, Cook R, LaPlante P, Barre P, Cartier P, Fay W, Goldstein M, Jindal K, Mandin H. Canadian Hemodialysis Morbidity Study. Am J Kidney Dis, 1992; 19: Foley R, Parfrey P, Harnett J, Kent G, Martin C, Murray D, Barre P. Clinical end echocardiographic disease in patients starting endstage renal disease therapy. Kidney Int, 1995; 47: Foley R. Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Seminars in Dialysis, 2003; 16: Francesco Locatelli, Pietro Pozzoni, Francesca Tentori, and Lucia Del Vecchio Epidemiology of cardiovascular risk in patients with chronic kidney disease Nephrol. Dial. Transplant., Aug 2003; 18: vii2 - vii9. 8. Parfrey P, Foley R, Harnett J, Kent G, Murray D, Barre P. The outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transpl, 1996; 11: Parfey P. S. Cardiac disease in dialysis patients: diagnostic, burden of disease, prognosis, risk factors and management. Nephrol. Dial. Transplant., Oct 2000; 15: Shlipak MG. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med 2003; 138: Kalinowski L, Dobrucki LW, Szczpanska-Konkel M et al. Third-generation betablockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 2003; 107:
12 12. Cice G, Ferrara L, D Andrea A et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy. J Am Coll Cardiol 2003; 41: Francesco Locatelli, Adrian Covic, Charles Chazot, Karel Leunissen, José Luño, and Mohammed Yaqoob Hypertension and cardiovascular risk assessment in dialysis patients Nephrol. Dial. Transplant., May 2004; 19: Silvergerg DS, Wexker D, Blum M, Schwartz D, Wollman Y, Iaina A. Erythropoietin should be part of congestive heart failure management. Kidney Int Suppl 2003; 87: S40 S Basil S. Lewis, Basheer Karkabi, Ronen Jaffe, Rita Yuval, Moshe Y. Flugelman, and David A. Halon Anaemia and heart failure: statement of the problem Nephrol. Dial. Transplant., Jul 2005; 20: vii3 - vii Nynke Cnossen, Jeroen P. Kooman, Constantijn J. Konings, Jan-Melle van Dantzig, Frank M. van der Sande, and Karel Leunissen Peritoneal dialysis in patients with congestive heart failure Nephrol. Dial. Transplant., July 2006; 21: ii63 - ii Alexander Kagan and Jayson Rapoport The role of peritoneal dialysis in the treatment of refractory heart failure Nephrol. Dial. Transplant., Jul 2005; 20: vii28 - vii Carmelo Libetta, Vincenzo Sepe, Manuela Zucchi, Patrizia Pisacco, Laura Cosmai, Federica Meloni, Carlo Campana, Teresa Rampino, Cristina Monti, Luigi Tavazzi, and Antonio Dal Canton. Intermittent Hemodiafiltration in refractory congestive heart failure: BNP and balance of inflammatory cytokines. Nephrol. Dial. Transplant., July 2007; 22: Christopher Chan, John S. Floras, Judith A. Miller, and Andreas Pierratos. Improvement in ejection fraction by nocturnal haemodialysis in end-stage renal 12
13 failure patients with coexisting heart failure. Nephrol. Dial. Transplant., Aug 2002; 17: Abbott KC, Hypolite IO, et al. The impact of renal transplantation on the incidence of congestive heart failure in patients with end stage renal disease due to diabetes. J. Nephrol 2001; 14; McGregor E, Jardine AG, Murray LS, et al. Pre-operative echocardiografic abnormalities and adverse outcome following renal transplantation. Nephrol. Dial. Transplant., 1998; 13: Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures N Engl J Med 1977;297: J. Muntwyler, Abetel G, Gruner C, et al. One year mortality among unselected outpatients with heart failure. European Heart Journal (2002) 23, Figures Figure 1. Spontaneous conversion from atrial fibrillation to sinusal rhythm after renal transplantation in a patient with severe heart failure. 13
14 Figure 2. Echocardiograms of a patient before renal transplant and after 12 months. Reduction of left posterior wall thickness from 12.2 to 11.3 mm at 12 months (P<0.05) 15 12,2 11, Before RT 12 mo. After RT Figure 3a. Reduction of LV end-diastolic diameter from 68.1 to 55.3 at 12 months (P<0.001) 68, , Figure 3b. -10 Before RT 12 mo. After RT LV end-systolic diameter from 57.2 to 39.3 at 12 months (P<0.001) 57,2 Before RT 39,3 12 mo. After RT 14
15 Figure 3c. 70 Pulmonary hypertension from 66 mmhg to 34,3 mmhg at 12 months (P<0.001) , Before RT 12 mo. After RT Figure 3d. Medium LVEF increased from 28,5% to 51% at 12 months (P<0.001) ,5 Before RT mo. After RT Figure 3e. Figure 4. Pulmonary radiography of a patient before renal transplant and after 12 months. 15
Left ventricular hypertrophy: why does it happen?
Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: 10.1093/ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital,
More informationCardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center
Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD
More informationBecause of important technologic advances achieved over
Anemia and Heart Failure in Chronic Kidney Disease Francesco Locatelli, Pietro Pozzoni, and Lucia Del Vecchio Cardiovascular disease is mainly responsible for the poor long-term survival observed in chronic
More informationReview of Cardiac Imaging Modalities in the Renal Patient. George Youssef
Review of Cardiac Imaging Modalities in the Renal Patient George Youssef ECHO Left ventricular hypertrophy (LVH) assessment Diastolic dysfunction Stress ECHO Cardiac CT angiography Echocardiography - positives
More informationOutline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies
Outline Pathophysiology: Mat Maurer, MD Irving Assistant Professor of Medicine Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology : Definitions An inability of the
More informationCardiovascular Diseases before and after Renal Transplantation
Med. J. Cairo Univ., Vol. 84, No. 1, June: 409-415, 2016 www.medicaljournalofcairouniversity.net Cardiovascular Diseases before and after Renal Transplantation TAREK H. EL-SHABONY, M.D.*; HUSSEIN M. HESHMATE,
More informationEnd stage renal disease (ESRD) is the irreversible deterioration of renal function
28 Journal of the association of physicians of india JANUARY 2014 VOL. 62 Original Article Echocardiographic Assessment of Cardiac Dysfunction in Patients of End Stage Renal Disease on Haemodialysis Mukesh
More informationARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER:
ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM General Instructions: The Heart Failure Hospital Record Abstraction Form is completed for all heart failure-eligible cohort hospitalizations. Refer to
More informationPathophysiology: Heart Failure
Pathophysiology: Heart Failure Mat Maurer, MD Irving Assistant Professor of Medicine Outline Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology Heart Failure: Definitions
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationTopic Page: congestive heart failure
Topic Page: congestive heart failure Definition: congestive heart f ailure from Merriam-Webster's Collegiate(R) Dictionary (1930) : heart failure in which the heart is unable to maintain an adequate circulation
More informationCongestive Heart Failure or Heart Failure
Congestive Heart Failure or Heart Failure Dr Hitesh Patel Ascot Cardiology Group Heart Failure Workshop April, 2014 Question One What is the difference between congestive heart failure and heart failure?
More informationObjectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009
Objectives Diastolic Heart Failure and Indications for Echocardiography in the Asian Population Damon M. Kwan, MD UCSF Asian Heart & Vascular Symposium 02.07.09 Define diastolic heart failure and differentiate
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationAntialdosterone treatment in heart failure
Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition
More informationDiastolic Heart Failure. Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012
Diastolic Heart Failure Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012 Disclosures Have spoken for Merck, Sharpe and Dohme Sat on a physician advisory
More informationOn Referral to our Unit
Case Presentation By Samah Ibrahim Abdel Meguid Idris, MD Internal Medicine & Nephrology Consultant Head of Hemodialysis Unit Ahmed Maher Hospital, Alexandria Patient Data MEA 27-year-old male patient
More informationPrevalence of cardiovascular damage in early renal disease
Nephrol Dial Transplant 2001) 16 wsuppl 2x: 7±11 Prevalence of cardiovascular damage in early renal disease Adeera Levin University of British Columbia, Renal Insuf ciency Clinic, Vancouver, Canada Abstract
More informationA Study of Clinical Profile in Chronic Kidney Disease with Special Reference to Echo and Electrocardiography
ORIGINAL ARTICLE A Study of Clinical 10.5005/jp-journals-10045-0072 Profile in Chronic Kidney Disease A Study of Clinical Profile in Chronic Kidney Disease with Special Reference to Echo and Electrocardiography
More informationEchocardiography analysis in renal transplant recipients
Original Research Article Echocardiography analysis in renal transplant recipients S.A.K. Noor Mohamed 1*, Edwin Fernando 2, 1 Assistant Professor, 2 Professor Department of Nephrology, Govt. Stanley Medical
More information03/07/ Background. + High Risk Features Are Prevalent in Dialysis Patients
+ When Does Cardiovascular Disease Preclude Consideration of Renal Transplantation? Kul Aggarwal, MD, MRCP (UK), FACC Professor of Clinical Medicine Division of Cardiology University of Missouri & Chief,
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationIn Vivo Animal Models of Heart Disease. Why Animal Models of Disease? Timothy A Hacker, PhD Department of Medicine University of Wisconsin-Madison
In Vivo Animal Models of Heart Disease Timothy A Hacker, PhD Department of Medicine University of Wisconsin-Madison Why Animal Models of Disease? Heart Failure (HF) Leading cause of morbidity and mortality
More informationBenefits from angiotensin-converting enzyme inhibition in patients with renal failure: latest results
European Heart Journal Supplements (2003) 5 (Supplement E), E18 E22 Benefits from angiotensin-converting enzyme inhibition in patients with renal failure: latest results B. Pannier, A.P. Guérin, S.J. Marchais
More informationDiagnosis & Management of Heart Failure. Abena A. Osei-Wusu, M.D. Medical Fiesta
Diagnosis & Management of Heart Failure Abena A. Osei-Wusu, M.D. Medical Fiesta Learning Objectives: 1) Become familiar with pathogenesis of congestive heart failure. 2) Discuss clinical manifestations
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationTAVR in patients with. End-Stage CKD or in Renal Replacement Therapy:
TAVR in patients with End-Stage CKD or in Renal Replacement Therapy: Special Considerations and Prevention of early Valve Failure Antonios Chalapas, MD, PhD, FESC THV & Hygeia Hospital Heart Team Athens,
More informationHeart Failure Dr ahmed almutairi Assistant professor internal medicin dept
Heart Failure Dr ahmed almutairi Assistant professor internal medicin dept (MBBS)(SBMD) Introduction Epidemiology Pathophysiology diastolic/systolic Risk factors Signs and symptoms Classification of HF
More informationEchocardiographic Assessment of Cardiac Dysfunction in Patients of Chronic Renal Failure
ORIGINAL ARTICLE JIACM 2003; 4(4): 296-303 Echocardiographic Assessment of Cardiac Dysfunction in Patients of Chronic Renal Failure Abstract S Agarwal*, P Dangri**, OP Kalra***, S Rajpal**** Objective
More informationAortic stenosis (AS) is common with the aging population.
New Insights Into the Progression of Aortic Stenosis Implications for Secondary Prevention Sanjeev Palta, MD; Anita M. Pai, MD; Kanwaljit S. Gill, MD; Ramdas G. Pai, MD Background The risk factors affecting
More informationHEART FAILURE. Study day November 2018 Sarah Briggs
HEART FAILURE Study day November 2018 Sarah Briggs Overview and Introduction This course is an introduction and overview of heart failure. Normal heart function and basic pathophysiology of heart failure
More informationDialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy
Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy Evan Adelstein, MD, FHRS John Gorcsan III, MD Samir Saba, MD, FHRS
More informationHEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
HEART FAILURE PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Understand the effects of heart failure in the body
More informationLEFT VENTRICULAR HYPERTROPHY AND CLINICAL OUTCOME IN CAPD PATIENTS
Peritoneal Dialysis International, Vol. 20, pp. 461 466 Printed in Canada. All rights reserved. 0896-8608/00 $3.00 +.00 Copyright 2000 International Society for Peritoneal Dialysis LEFT VENTRICULAR HYPERTROPHY
More informationRENAL TRANSPLANT PATIENTS WITH HIGH-FLOW AVF: WHEN & HOW TO INTERVENE Stuart Greenstein, MD Abdominal Organ Transplant Division Albert Einstein
RENAL TRANSPLANT PATIENTS WITH HIGH-FLOW AVF: WHEN & HOW TO INTERVENE Stuart Greenstein, MD Abdominal Organ Transplant Division Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY
More informationAssessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington
Assessing Cardiac Risk in Noncardiac Surgery Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Disclosure None. I have no conflicts of interest, financial or otherwise. CME
More informationReport and Opinion 2016;8(12)
Prevalence of calcific aortic valve stenosis in haemodialysis patients at AL Hussein University Hospital. Ahmed Alaa Saad 1, Sami H. Nooh 2, Osama A. Khamis 1, Magdy E. Mohamed 1, Mohamed Abdelhafez 1
More informationProgram Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationInnovation therapy in Heart Failure
Innovation therapy in Heart Failure P. Laothavorn September 2015 Topics of discussion Basic Knowledge about heart failure Standard therapy New emerging therapy References: standard Therapy in Heart Failure
More informationIndex of subjects. effect on ventricular tachycardia 30 treatment with 101, 116 boosterpump 80 Brockenbrough phenomenon 55, 125
145 Index of subjects A accessory pathways 3 amiodarone 4, 5, 6, 23, 30, 97, 102 angina pectoris 4, 24, 1l0, 137, 139, 140 angulation, of cavity 73, 74 aorta aortic flow velocity 2 aortic insufficiency
More informationHeart Failure. Cardiac Anatomy. Functions of the Heart. Cardiac Cycle/Hemodynamics. Determinants of Cardiac Output. Cardiac Output
Cardiac Anatomy Heart Failure Professor Qing ZHANG Department of Cardiology, West China Hospital www.blaufuss.org Cardiac Cycle/Hemodynamics Functions of the Heart Essential functions of the heart to cover
More informationThe right heart: the Cinderella of heart failure
The right heart: the Cinderella of heart failure Piotr Ponikowski, MD, PhD, FESC Medical University, Centre for Heart Disease Clinical Military Hospital Wroclaw, Poland none Disclosure Look into the Heart
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationThe Management of Heart Failure after Biventricular Pacing
The Management of Heart Failure after Biventricular Pacing Juan M. Aranda, Jr., MD University of Florida College of Medicine, Division of Cardiovascular Medicine, Gainesville, Florida Approximately 271,000
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM
ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM ID NUMBER: FORM NAME: H F A DATE: 10/01/2015 VERSION: D CONTACT YEAR NUMBER: FORM SEQUENCE NUMBER: General Instructions: The Heart Failure Hospital Record
More informationTreating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment
ESC 2012 27Aug - 3Sep, 2012, Munich, Germany Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment Marco Metra, MD, FESC Cardiology University
More informationCardiorenal and Renocardiac Syndrome
And Renocardiac Syndrome A Vicious Cycle Cardiorenal and Renocardiac Syndrome Type 1 (acute) Acute HF results in acute kidney injury Type 2 Chronic cardiac dysfunction (eg, chronic HF) causes progressive
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationValue of echocardiography in chronic dyspnea
Value of echocardiography in chronic dyspnea Jahrestagung Schweizerische Gesellschaft für /Schweizerische Gesellschaft für Pneumologie B. Kaufmann 16.06.2016 Chronic dyspnea Shortness of breath lasting
More informationPeripartum Cardiomyopathy. Lavanya Rai Manipal
Peripartum Cardiomyopathy Lavanya Rai Manipal Definition - PPCM - Dilated cardiomyopathy of unknown cause resulting in cardiac failure that occurs in the peripartum period in women without any preexisting
More informationIntermittent low dose digoxin may be effective and safe in patients with chronic heart failure undergoing maintenance hemodialysis
EXPERIMENTAL AND THERAPEUTIC MEDICINE 8: 1689-1694, 2014 Intermittent low dose digoxin may be effective and safe in patients with chronic heart failure undergoing maintenance hemodialysis XIAOZHAO LI 1,
More informationNora Goldschlager, M.D. SFGH Division of Cardiology UCSF
CLASSIFICATION OF HEART FAILURE Nora Goldschlager, M.D. SFGH Division of Cardiology UCSF DISCLOSURES: NONE CLASSIFICATION C OF HEART FAILURE NYHA I IV New paradigm Stage A: Pts at high risk of developing
More informationPathophysiology: Heart Failure. Objectives
Pathophysiology: Heart Failure Mat Maurer, MD Irving Assistant Professor of Clinical Medicine Objectives At the conclusion of this seminar, learner will be able to: 1. Define heart failure as a clinical
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationLeft atrial function. Aliakbar Arvandi MD
In the clinic Left atrial function Abstract The left atrium (LA) is a left posterior cardiac chamber which is located adjacent to the esophagus. It is separated from the right atrium by the inter-atrial
More informationEchocardiographic changes and risk factors for left ventricular hypertrophy in children and adolescents after renal transplantation
Pediatr Transplantation 2004: 8: 249 254 Printed in UK. All rights reserved Copyright Ó 2004 Blackwell Munksgaard Pediatric Transplantation Echocardiographic changes and risk factors for left ventricular
More informationEvaluation of a diagnostic pathway in heart failure in primary care, using electrocardiography and brain natriuretic peptide guided echocardiography
Evaluation of a diagnostic pathway in heart failure in primary care, using electrocardiography and brain natriuretic peptide guided echocardiography Rebecka Karlsson Pardeep Jhund 1 Material and methods
More informationChapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure
Chapter 10 Congestive Heart Failure Learning Objectives Explain concept of polypharmacy in treatment of congestive heart failure Explain function of diuretics Learning Objectives Discuss drugs used for
More informationProtocol Identifier Subject Identifier Visit Description. [Y] Yes [N] No. [Y] Yes [N] N. If Yes, admission date and time: Day Month Year
PAST MEDICAL HISTORY Has the subject had a prior episode of heart failure? o Does the subject have a prior history of exposure to cardiotoxins, such as anthracyclines? URGENT HEART FAILURE VISIT Did heart
More informationSinus tachycardia related to tacrolimus after kidney transplantation in children and young adults
The Turkish Journal of Pediatrics 2015; 57: 587-591 Original Sinus tachycardia related to tacrolimus after kidney in children and young adults İlkay Erdoğan 1, Yelda Bilginer 2, Ali Düzova 2, Nesrin Beşbaş
More informationHeart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre
Heart Failure in Women: More than EF? Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre Overview Review pathophysiology as it relates to diagnosis and management Rational approach to workup:
More informationLV geometric and functional changes in VHD: How to assess? Mi-Seung Shin M.D., Ph.D. Gachon University Gil Hospital
LV geometric and functional changes in VHD: How to assess? Mi-Seung Shin M.D., Ph.D. Gachon University Gil Hospital LV inflow across MV LV LV outflow across AV LV LV geometric changes Pressure overload
More informationHypertension in Aortic Valve Disease
Hypertension in Aortic Valve Disease Hanna M. Nosseir MRCP, FRCP Head of Cardiology department Galaa Military Medical Complex Aortic stenosis: Introduction Arterial hypertension and aortic stenosis are
More informationCharles Spencer MD, FRCP Consultant Cardiologist Mid Staffs NHSFT
Charles Spencer MD, FRCP Consultant Cardiologist Mid Staffs NHSFT Key Messages Heart Failure is Common Heart failure is complex Heart Failure is a major issue for the NHS Heart Failure has a worse prognosis
More informationMaher Fouad Ramzy; MD, FACP Professor of Renal Medicine, Cairo University
Hypertension in Hemodialysis Patient Maher Fouad Ramzy; MD, FACP Professor of Renal Medicine, Cairo University Mechanism of HTN in HD patients Volume-dependent HTN ECV expansion. Volume-independent HTN
More informationIncidence. 4.8 million in the United States. 400,000 new cases/year. 20 million patients with asymptomatic LV dysfunction
Heart Failure Diagnosis According to the Working Group in Heart Failure, CHF is a syndrome where the diagnosis has the following essential components: A combination of: Symptoms, typically breathlessness
More informationHeart Failure. Acute. Plasma [NE] (pg/ml) 24 Hours. Chronic
Heart Failure Heart failure is the inability of the heart to deliver sufficient blood to the tissues to ensure adequate oxygen supply. Clinically it is characterized by signs of volume overload or symptoms
More informationHypertension and diabetic nephropathy
Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney
More informationTHE KIDNEY AND SLE LUPUS NEPHRITIS
THE KIDNEY AND SLE LUPUS NEPHRITIS JACK WATERMAN DO FACOI 2013 NEPHROLOGY SIR RICHARD BRIGHT TERMINOLOGY RENAL INSUFFICIENCY CKD (CHRONIC KIDNEY DISEASE) ESRD (ENDSTAGE RENAL DISEASE) GLOMERULONEPHRITIS
More informationPerioperative management of a patient with left ventricular failure
Perioperative management of a patient with left ventricular failure Ramkumar Venkateswaran, MD Professor of Anaesthesiology Kasturba Medical College, Manipal University INTRODUCTION Congestive heart failure
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationMedical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece
Medical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece Disclosures Grants: ALARM investigator received research grants
More informationAdvances in Peritoneal Dialysis, Vol. 29, 2013
Advances in Peritoneal Dialysis, Vol. 29, 2013 Takeyuki Hiramatsu, 1 Takahiro Hayasaki, 1 Akinori Hobo, 1 Shinji Furuta, 1 Koki Kabu, 2 Yukio Tonozuka, 2 Yoshiyasu Iida 1 Icodextrin Eliminates Phosphate
More informationState-of-the-Art Management of Chronic Systolic Heart Failure
State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures
More information2016 Update to Heart Failure Clinical Practice Guidelines
2016 Update to Heart Failure Clinical Practice Guidelines Mitchell T. Saltzberg, MD, FACC, FAHA, FHFSA Medical Director of Advanced Heart Failure Froedtert & Medical College of Wisconsin Stages, Phenotypes
More informationPathophysiology: Left To Right Shunts
Pathophysiology: Left To Right Shunts Daphne T. Hsu, MD dh17@columbia.edu Learning Objectives Learn the relationships between pressure, blood flow, and resistance Review the transition from fetal to mature
More informationNCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT
NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT CONTENTS PATIENTS ADMITTED WITH HEART FAILURE...4 Demographics... 4 Trends in Symptoms... 4 Causes and Comorbidities
More informationCongestive Heart Failure Patient Profile. Patient Identity - Mr. Douglas - 72 year old man - No drugs, smokes, moderate social alcohol consumption
Congestive Heart Failure Patient Profile Patient Identity - Mr. Douglas - 72 year old man - No drugs, smokes, moderate social alcohol consumption Chief Complaint - SOB - When asked: Increasing difficulty
More informationFattori condizionanti la sopravvivenza nel paziente con scompenso di cuore
Journal Club 13 Febbraio 2008 Fattori condizionanti la sopravvivenza nel paziente con scompenso di cuore Intissar Sleiman Prevalence of heart failure by sex and age (NHANES:1999-2004) Circulation 2007
More informationCardiovascular Disorders. Heart Disorders. Diagnostic Tests for CV Function. Bio 375. Pathophysiology
Cardiovascular Disorders Bio 375 Pathophysiology Heart Disorders Heart disease is ranked as a major cause of death in the U.S. Common heart diseases include: Congenital heart defects Hypertensive heart
More informationChapter 4: Cardiovascular Disease in Patients with CKD
Chapter 4: Cardiovascular Disease in Patients with CKD The prevalence of cardiovascular disease (CVD) was 65.8% among patients aged 66 and older who had chronic kidney disease (CKD), compared to 31.9%
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
More informationHeart Failure. Dr. William Vosik. January, 2012
Heart Failure Dr. William Vosik January, 2012 Questions for clinicians to ask Is this heart failure? What is the underlying cause? What are the associated disease processes? Which evidence-based treatment
More informationEchocardiographic assessment of left ventricular hypertrophy in patients of chronic kidney disease
International Journal of Research in Medical Sciences Behera BK et al. Int J Res Med Sci. 2017 Nov;5(11):4783-4788 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Original Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20174672
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationIdentification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study
Identification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study Dr. Antonio Magaña M.D. (on behalf I-PREFER investigators group) Stockholm, Sweden, August
More informationDiagnosis and management of Chronic Heart Failure in 2018: What does NICE say? PCCS Meeting Issues and Answers Conference Nottingham
Diagnosis and management of Chronic Heart Failure in 2018: What does NICE say? PCCS Meeting Issues and Answers Conference Nottingham NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Chronic heart failure
More informationKDIGO LESSONS LEARNED FROM NEPHROLOGY TRIALS WITH RESPECT TO HEART FAILURE
LESSONS LEARNED FROM NEPHROLOGY TRIALS WITH RESPECT TO HEART FAILURE Dr. Christopher T Chan Director Division of Nephrology University Health Network Professor of Medicine University of Toronto Disclosure
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 9: Cardiovascular Disease in Patients With ESRD Cardiovascular disease is common in ESRD patients, with atherosclerotic heart disease and congestive heart
More informationDIASTOLIC HEART FAILURE
DIASTOLIC HEART FAILURE M Mohsen Ibrahim, MD Alexandria, Proposed Criteria for Diastolic Heart Failure ESC Working Group (EHJ 1998) CHF signs/symptoms EF 45% Hemodynamic or echo evidence of diastolic dysfunction
More informationPathophysiology: Left To Right Shunts
Pathophysiology: Left To Right Shunts Daphne T. Hsu, MD dh17@columbia.edu Learning Objectives Learn the relationships between pressure, blood flow, and resistance Review the transition from fetal to mature
More informationDiastolic Dysfunction: Hypertension to Hypertrophy to Heart Failure
Diastolic Dysfunction: Hypertension to Hypertrophy to Heart Failure Dr. Shelley Zieroth FRCPC Assistant Professor, Cardiology, University of Manitoba Director of Cardiac Transplant and Heart Failure Clinics
More informationCopeptin in heart failure: Associations with clinical characteristics and prognosis
Copeptin in heart failure: Associations with clinical characteristics and prognosis D. Berliner, N. Deubner, W. Fenske, S. Brenner, G. Güder, B. Allolio, R. Jahns, G. Ertl, CE. Angermann, S. Störk for
More informationPRESENTER DISCLOSURE INFORMATION. There are no potential conflicts of interest regarding current presentation
PRESENTER DISCLOSURE INFORMATION There are no potential conflicts of interest regarding current presentation Better synchrony and diastolic function for septal versus apical right ventricular permanent
More informationDialysis Initiation and Optimal Vascular Access: Outcomes and Mortality
Dialysis Initiation and Optimal Vascular Access: Outcomes and Mortality Shannon H. Norris, BSN, RN June 6, 2018 Dialysis Initiation and Optimal Vascular Access: Outcomes and Mortality DISCUSSION: End Stage
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationImpact of Dialysis Access Fistula on Cardiac Function After Kidney Transplantation
Dialysis Impact of Dialysis Access Fistula on Cardiac Function After Kidney Transplantation Mohammad Javad Soleimani, 1 Hosein Shahrokh, 1 Pejman Shadpour, 1 Majid Shirani, 2 Said Arasteh 1 Original Paper
More information